Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma

Next Previous
Search
Trial Profile

A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plerixafor (Primary) ; Filgrastim
  • Indications Non-Hodgkin's lymphoma; Stem cell mobilisation
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi

Most Recent Events

  • 01 Nov 2018 Results assessing efficacy and safety of plerixafor, published in the International Journal of Hematology.
  • 29 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 17 Feb 2016 Planned End Date changed from 1 Apr 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top